Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
A 2026 Cochrane review examined thymosin-α1 for chronic hepatitis B. Learn what researchers found about its potential benefits and current evidence limitations.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may directly protect neurons via orexin receptor signaling. Learn what this study means for stroke and neuroprotection.
By Peptide Association Research Team
New research explores how SS-31 peptide nanoparticles may restore mitochondrial function and reduce inflammation in ulcerative colitis. Learn what the study found.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may protect neurons by engaging orexin receptors and suppressing necroptosis. Learn what the study found and its implications.
By Peptide Association Research Team
A 2026 review in Current Pain and Headache Reports examines regenerative peptides for chronic pain and tissue repair. Learn what the evidence shows.
By Peptide Association Research Team
New research explores how microvascular dysfunction and nerve signaling disruption cause silent myocardial ischemia in diabetic patients—without warning symptoms.
By Peptide Association Research Team
A 2026 clinical trial suggests Phellinus igniarius decoction may help restore immune function in colorectal cancer patients following chemotherapy. Read the findings.
By Peptide Association Research Team
A 2026 clinical review explores regenerative peptides like BPC-157, TB-4, and GHK-Cu for tissue repair and chronic pain. Here's what the evidence says.
By Peptide Association Research Team
A 2026 review examines regenerative peptides like BPC-157, TB-500, and GHK-Cu for chronic pain and tissue repair. Learn what the evidence says.
By Peptide Association Research Team
New research suggests the SS-31 peptide may help treat ulcerative colitis by restoring mitochondrial function and reprogramming immune cells. Learn what the study found.
By Peptide Association Research Team
A 2026 review examines regenerative peptides for chronic pain and tissue repair. Learn what the research suggests and how to find a qualified provider.
By Peptide Association Research Team
New research shows machine learning may accelerate peptide and protein drug formulation development. Learn what this 2026 study means for peptide therapies.
By Peptide Association Research Team
New research links perioperative opioid use to hippocampal mitochondrial dysfunction and lasting cognitive impairment in aged rats. What does it mean for patients?
By Peptide Association Research Team
New research in aged rats suggests opioid use after surgery disrupts hippocampal mitochondria, contributing to long-term cognitive decline. Learn what the findings mean.
By Peptide Association Research Team
A 2026 scoping review in the American Journal of Sports Medicine examines peptide supplement evidence for musculoskeletal recovery. Here's what the data shows.
By Peptide Association Research Team
New research links mitochondrial dysfunction to postoperative cognitive decline. Learn what the science suggests and how emerging therapies may help protect brain health.
By Peptide Association Research Team
A 2026 review examines approved and unapproved peptides for musculoskeletal injuries and athletic performance. Learn what the evidence actually shows.
By Peptide Association Research Team
A 2026 scoping review in the American Journal of Sports Medicine examines BPC-157, TB-500, MK-677, and other peptides for musculoskeletal recovery.
By Peptide Association Research Team
New research links perioperative opioid use to hippocampal mitochondrial dysfunction in aged rats, suggesting a potential target for treating postoperative cognitive decline.
By Peptide Association Research Team
A 2026 study in 3 Biotech found BPC-157 chitosan hydrogel showed promising antibacterial and drug delivery properties. Learn what the research suggests.
By Peptide Association Research Team
New research explores how mitochondrial dysfunction drives postoperative cognitive decline and which targeted therapies show neuroprotective promise in preclinical studies.
By Peptide Association Research Team
A 2026 study in 3 Biotech fabricated a BPC-157 chitosan hydrogel showing promising antibacterial and biocompatible properties for future biomedical use.
By Peptide Association Research Team
New research explores how mitochondrial dysfunction drives postoperative cognitive decline and which peptide-based therapies show promise in preclinical studies.
By Peptide Association Research Team
New research explores a BPC-157 chitosan hydrogel with strong encapsulation, antibacterial properties, and biocompatibility. Learn what the findings suggest.
By Peptide Association Research Team